Current role of chemotherapy protectors in cancer treatment
Bol. Asoc. Méd. P. R
;
89(10/12): 184-188, Oct.-Dec. 1997.
Artigo
em Inglês
| LILACS
| ID: lil-411426
ABSTRACT
The administration of full doses of chemotherapy according to an established schedule improves the response rate and duration of response in cancer patients. However, frequently there are delays in therapy due to dose-limiting side effects and chemotherapy could affect permanently normal tissues. This has led to the development of chemotherapy protectors and of rescue agents in the past years. We will discuss some of these new agents and their use in cancer treatment. Some of these agents include amifostine (Ethyol), dexrazoxane (Zinecard), mesna (Mesnex), leucovorin, G-CSF, GM CSF, recombinant erythropoietin and thrombopoietin. Oncologists must learn the adequate use of different strategies in reducing chemotherapy toxicity in order to improve both the quality and quantity of life of cancer patients
Buscar no Google
Índice:
LILACS (Américas)
Assunto principal:
Neoplasias
/
Antineoplásicos
Limite:
Humanos
Idioma:
Inglês
Revista:
Bol. Asoc. Méd. P. R
Assunto da revista:
Medicina
Ano de publicação:
1997
Tipo de documento:
Artigo
País de afiliação:
Porto Rico
Instituição/País de afiliação:
Centro Médico Mail Station/PR
Similares
MEDLINE
...
LILACS
LIS